A citation-based method for searching scientific literature

Chintan V Dave, Seoyoung C Kim, Allison B Goldfine, Robert J Glynn, Angela Tong, Elisabetta Patorno. Circulation 2021
Times Cited: 3







List of co-cited articles
1 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen,[...]. Eur Heart J 2020
812
66

Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
Fabio Marsico, Stefania Paolillo, Paola Gargiulo, Dario Bruzzese, Simona Dell'Aversana, Immacolata Esposito, Francesco Renga, Luca Esposito, Caterina Marciano, Santo Dellegrottaglie,[...]. Eur Heart J 2020
34
33


2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies. Diabetes Care 2020
290
33

Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
Chrysanthi Mantsiou, Thomas Karagiannis, Panagiota Kakotrichi, Konstantinos Malandris, Ioannis Avgerinos, Aris Liakos, Apostolos Tsapas, Eleni Bekiari. Diabetes Obes Metab 2020
6
33

The Lancet Commission on diabetes: using data to transform diabetes care and patient lives.
Juliana C N Chan, Lee-Ling Lim, Nicholas J Wareham, Jonathan E Shaw, Trevor J Orchard, Ping Zhang, Eric S H Lau, Björn Eliasson, Alice P S Kong, Majid Ezzati,[...]. Lancet 2021
28
33

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
Julio Rosenstock, Steven E Kahn, Odd Erik Johansen, Bernard Zinman, Mark A Espeland, Hans J Woerle, Egon Pfarr, Annett Keller, Michaela Mattheus, David Baanstra,[...]. JAMA 2019
163
33

Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease.
Suzanne V Arnold, James A de Lemos, Robert S Rosenson, Christie M Ballantyne, Yuyin Liu, Katherine E Mues, Shushama Alam, Mary Elliott-Davey, Deepak L Bhatt, Christopher P Cannon,[...]. Circulation 2019
34
33


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
33


Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults.
Elisabetta Patorno, Ajinkya Pawar, Lily G Bessette, Dae H Kim, Chintan Dave, Robert J Glynn, Medha N Munshi, Sebastian Schneeweiss, Deborah J Wexler, Seoyoung C Kim. Diabetes Care 2021
3
33

Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities.
Emily Brown, John P H Wilding, Thomas M Barber, Uazman Alam, Daniel J Cuthbertson. Obes Rev 2019
30
33

Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis.
Yue Fei, Man-Fung Tsoi, Bernard Man Yung Cheung. Cardiovasc Diabetol 2019
43
33

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
33

Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Uli C Broedl, Hans J Woerle. Diabetes Care 2014
250
33



Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis.
Da-Peng Zhang, Li Xu, Le-Feng Wang, Hong-Jiang Wang, Feng Jiang. Cardiovasc Diabetol 2020
13
33

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Søren L Kristensen, Rasmus Rørth, Pardeep S Jhund, Kieran F Docherty, Naveed Sattar, David Preiss, Lars Køber, Mark C Petrie, John J V McMurray. Lancet Diabetes Endocrinol 2019
319
33

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
33

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetes Care 2018
991
33

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
492
33


Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, KyungAh Im, Erica L Goodrich, Remo H M Furtado, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn,[...]. Circulation 2019
233
33

Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials.
Dario Giugliano, Maria Ida Maiorino, Miriam Longo, Giuseppe Bellastella, Paolo Chiodini, Katherine Esposito. Endocrine 2019
10
33

Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
D Patoulias, A Katsimardou, M-S Kalogirou, I Zografou, M Toumpourleka, K Imprialos, K Stavropoulos, I Stergiou, C Papadopoulos, M Doumas. Diabetes Metab 2020
1
100

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
33

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
916
33

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
33

Diabetes care--improvement through measurement.
Björn Eliasson, Soffia Gudbjörnsdottir. Diabetes Res Clin Pract 2014
77
33



Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
Matthew M Y Lee, Katriona J M Brooksbank, Kirsty Wetherall, Kenneth Mangion, Giles Roditi, Ross T Campbell, Colin Berry, Victor Chong, Liz Coyle, Kieran F Docherty,[...]. Circulation 2021
37
33

Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
Elvira D'Andrea, Aaron S Kesselheim, Jessica M Franklin, Emily H Jung, Spencer Phillips Hey, Elisabetta Patorno. Cardiovasc Diabetol 2020
5
33

Review of 103 Swedish Healthcare Quality Registries.
L Emilsson, B Lindahl, M Köster, M Lambe, J F Ludvigsson. J Intern Med 2015
196
33

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Melanie J Davies, Richard Bergenstal, Bruce Bode, Robert F Kushner, Andrew Lewin, Trine Vang Skjøth, Arne Haahr Andreasen, Christine Bjørn Jensen, Ralph A DeFronzo. JAMA 2015
344
33

SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL.
Matthew A Cavender, Anna Norhammar, Kåre I Birkeland, Marit Eika Jørgensen, John P Wilding, Kamlesh Khunti, Alex Z Fu, Johan Bodegård, Betina T Blak, Eric Wittbrodt,[...]. J Am Coll Cardiol 2018
59
33

Avoidable flaws in observational analyses: an application to statins and cancer.
Barbra A Dickerman, Xabier García-Albéniz, Roger W Logan, Spiros Denaxas, Miguel A Hernán. Nat Med 2019
55
33

2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies. Diabetologia 2020
136
33



Years of potential life lost in pre-diabetes and diabetes mellitus: data from a 40-year follow-up of the Israel study on Glucose intolerance, Obesity and Hypertension.
Micha Rapoport, Angela Chetrit, Dror Cantrell, Ilya Novikov, Jesse Roth, Rachel Dankner. BMJ Open Diabetes Res Care 2021
1
100

Global prevalence of metabolic syndrome among patients with type I diabetes mellitus: a systematic review and meta-analysis.
Rebuma Belete, Zerihun Ataro, Ahmedmenewer Abdu, Merga Sheleme. Diabetol Metab Syndr 2021
1
100

The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes.
Klara R Klein, Jennifer L R Freeman, Imogene Dunn, Chris Dvergsten, M Sue Kirkman, John B Buse, Carmen Valcarce. Diabetes Care 2021
2
50

Trends in the incidence of diagnosed diabetes: a multicountry analysis of aggregate data from 22 million diagnoses in high-income and middle-income settings.
Dianna J Magliano, Lei Chen, Rakibul M Islam, Bendix Carstensen, Edward W Gregg, Meda E Pavkov, Linda J Andes, Ran Balicer, Marta Baviera, Elise Boersma-van Dam,[...]. Lancet Diabetes Endocrinol 2021
6
33


Quantifying the Sex-Race/Ethnicity-Specific Burden of Obesity on Incident Diabetes Mellitus in the United States, 2001 to 2016: MESA and NHANES.
Natalie A Cameron, Lucia C Petito, Megan McCabe, Norrina B Allen, Matthew J O'Brien, Mercedes R Carnethon, Sadiya S Khan. J Am Heart Assoc 2021
2
50

GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis.
Thomas Karagiannis, Apostolos Tsapas, Eleni Athanasiadou, Ioannis Avgerinos, Aris Liakos, David R Matthews, Eleni Bekiari. Diabetes Res Clin Pract 2021
2
50



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.